Toggle light / dark theme

Researchers discover placental stem cells that can regenerate heart after heart attack

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta known as Cdx2 cells can regenerate healthy heart cells after heart attacks in animal models. The findings, published in the May 20 issue of Proceedings of the National Academy of Sciences (PNAS), may represent a novel treatment for regenerating the heart and other organs.

“Cdx2 cells have historically been thought to only generate the placenta in early embryonic development, but never before were shown to have the ability to regenerate other organs, which is why this is so exciting. These findings may also pave the way to regenerative therapy of other organs besides the heart,” said principal investigator Hina Chaudhry, MD, Director of Cardiovascular Regenerative Medicine at the Icahn School of Medicine at Mount Sinai. “They almost seem like a super-charged population of , in that they can target the site of an injury and travel directly to the injury through the and are able to avoid rejection by the host .”

This team of Mount Sinai researchers had previously discovered that a mixed population of mouse placental stem cells can help the hearts of pregnant female mice recover after an injury that could otherwise lead to . In that study, they showed that the placental stem cells migrated to the mother’s heart and directly to the site of the heart injury. The stem cells then programmed themselves as beating heart cells to help the repair process.

Read more

AI Is Rapidly Augmenting Healthcare and Longevity

Conclusion

As Nvidia CEO Jensen Huang has stated, “Software ate the world, but AI is going to eat software.” Extrapolating this statement to a more immediate implication, AI will first eat healthcare, resulting in dramatic acceleration of longevity research and an amplification of the human healthspan.

Next week, I’ll continue to explore this concept of AI systems in healthcare.


Commander (ret) Dr. Luis Alvarez, Director of Organ Manufacturing, United Therapeutics, and Co-Founder of GDF11 Harvard spin-out Elevian and MIT spin-out Theradaptive — ideaXme Show — Ira Pastor

Ending Age-Related Diseases Conference: May Update

May is almost over, so it’s time to check in with the Ending Age-Released Diseases conference and see how things are developing with the event.

If you’re unfamiliar with us, we’re hosting our second annual conference at the Cooper Union in New York City on July 11-12th this year. It will feature some of the leading names in both aging research and biotech business and investment coming together to share their knowledge and insights with the audience.

Aging research is on the cusp of some major breakthroughs in the battle against age-related diseases, and we invite you to join us for an action-packed event filled with exciting talks and discussion panels featuring some of the leaders of aging research and the biotech business.

Read more

Rejuvenate Bio Using Gene Therapy Has Reversed Aging Effects in Mice and Dogs

Is it me? Or am I the only one who wishes George Church was not so secretive? https://www.nextbigfuture.com/2019/05/rejuvenate-bio-using-g…dogs.html?


Harvard Genetics Giant Geroge Church and Noah Davidsohn, a former postdoc in his lab, have engaged in a secretive antiaging venture called Rejuvenate Bio. They are making old dogs new. They have conducted gene therapy on beagles and are currently advertising for Cavalier King Charles spaniels to use gene therapy to fix their hearts.

They have identified many other targets for gene-based interventions, studying a database of aging-related genes.

Most of the work was done in mice, where they have extended the life of mice by a factor of two. Nextbigfuture notes that this would mean mice would live 6 years with treatment instead of 3 years.

Read more

Future of human population

In 2018, researchers at the Biogerontology Research Foundation and the International Longevity Alliance submitted a joint proposal to the World Health Organization to re-classify aging as a disease. Months later, 11th Revision of the International Classification of Diseases (ICD-11) officially introduced some aging-related conditions such as age-associated cognitive decline.

This matters because, for the first time in human history, the once natural process of aging is becoming recontextualized as a condition to be treated and prevented. This will gradually lead to pharmaceutical companies and governments redirecting funding to new drugs and therapies that not only extend human life expectancy but reverse the effects of aging entirely.

Thus far, people in developed nations have seen their average life expectancy rise from ~35 in 1820 to 80 in 2003. And with the advances you’re about to learn about, you’ll see how that progression will continue until 80 becomes the new 40. In fact, the first humans expected to live to 150 may have already been born.

Read more

/* */